Is there a role for immune checkpoint inhibitors in chordoma?

被引：2
作者：
Assi, Tarek [1 ]
机构：
[1] St Joseph Univ, Fac Med, Dept Hematol Oncol, Beirut, Lebanon
来源：
IMMUNOTHERAPY | 2021年 / 13卷 / 12期
关键词：
checkpoint inhibitors; chordoma; immunotherapy; PD-1; rare tumor; sarcoma; treatment; TUMOR-INFILTRATING LYMPHOCYTES; SINGLE-ARM; OPEN-LABEL; SARCOMA; PEMBROLIZUMAB; EXPRESSION; NIVOLUMAB; PD-L1; MULTICENTER; IPILIMUMAB;
D O I：
10.2217/imt-2021-0066
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：967 / 970
页数：4
相关论文
共 25 条
  • [1] Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?
    Assi, Tarek
    Cesne, Axel Le
    Mir, Olivier
    [J]. IMMUNOTHERAPY, 2021, 13 (02) : 91 - 93
  • [2] Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?
    Assi, Tarek
    [J]. FUTURE ONCOLOGY, 2019, 15 (28) : 3185 - 3187
  • [3] Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival
    Bai, Jiwei
    Shi, Jianxin
    Li, Chuzhong
    Wang, Shuai
    Zhang, Tongwu
    Hua, Xing
    Zhu, Bin
    Koka, Hela
    Wu, Ho-Hsiang
    Song, Lei
    Wang, Difei
    Wang, Mingyi
    Zhou, Weiyin
    Ballew, Bari J.
    Hicks, Belynda
    Mirabello, Lisa
    Parry, Dilys M.
    Zhai, Yixuan
    Li, Mingxuan
    Du, Jiang
    Wang, Junmei
    Zhang, Shuheng
    Liu, Qian
    Zhao, Peng
    Gui, Songbai
    Goldstein, Alisa M.
    Zhang, Yazhuo
    Yang, Xiaohong R.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [4] High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSe Pembrolizumab study
    Blay, J-Y.
    Chevret, S.
    Penel, N.
    Bertucci, F.
    Bompas, E.
    Saada-Bouzid, E.
    Eymard, J-C.
    Lotz, J-P.
    Coquan, E.
    Schott, R.
    Soulie, P.
    Linassier, C.
    Le Cesne, A.
    Brahmi, M.
    Hoog-Labouret, N.
    Legrand, F.
    Simon, C.
    Lamrani-Ghaouti, A.
    Ray-Coquard, I. L.
    Massard, C.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S972 - S972
  • [5] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population
    Brzezianska, Ewa
    Karbownik, Malgorzata
    Migdalska-Sek, Monika
    Pastuszak-Lewandoska, Dorota
    Wloch, Jan
    Lewinski, Andrzej
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) : 26 - 35
  • [6] Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
    D'Angelo, Sandra P.
    Mahoney, Michelle R.
    Van Tine, Brian A.
    Atkins, James
    Milhem, Mohammed M.
    Jahagirdar, Balkrishna N.
    Antonescu, Cristina R.
    Horvath, Elise
    Tap, William D.
    Schwartz, Gary K.
    Streicher, Howard
    [J]. LANCET ONCOLOGY, 2018, 19 (03) : 416 - 426
  • [7] Immunotherapy in sarcoma: combinations or single agents? In whom?
    Dufresne, Armelle
    Brahmi, Mehdi
    [J]. CURRENT OPINION IN ONCOLOGY, 2020, 32 (04) : 339 - 343
  • [8] Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
    Feng, Yong
    Shen, Jacson
    Gao, Yan
    Liao, Yunfei
    Cote, Gregory
    Choy, Edwin
    Chebib, Ivan
    Mankin, Henry
    Hornicek, Francis
    Duan, Zhenfeng
    [J]. ONCOTARGET, 2015, 6 (13) : 11139 - 11149
  • [9] Fletcher C.D.M., 2013, WHO CLASSIFICATION T, V4th
  • [10] Chordoma: update on disease, epidemiology, biology and medical therapies
    Frezza, Anna Maria
    Botta, Laura
    Trama, Annalisa
    Dei Tos, Angelo P.
    Stacchiotti, Silvia
    [J]. CURRENT OPINION IN ONCOLOGY, 2019, 31 (02) : 114 - 120
123